Supply of Technetium-99m (Tc99m) Bicisate Radiopharmaceutical

The contract seeks the supply of clinical-grade Technetium-99m Bicisate, a radiopharmaceutical used in nuclear medicine for myocardial perfusion imaging, to support diagnostic procedures within the Department of Veterans Affairs healthcare system. The solicitation is classified as a subcontract under NAICS code 325412, which pertains to pharmaceutical preparation manufacturing, indicating the need for a supplier with expertise in producing radiopharmaceuticals that meet stringent clinical and regulatory standards. The opportunity was posted on July 20, 2026, with a response deadline of August 13, 2026, at 3:00 PM, allowing potential vendors a limited timeframe to submit proposals that demonstrate compliance with quality, safety, and delivery requirements for nuclear medicine applications. The contracting activity is managed by the 250-NETWORK Contract Office 10 under the Department of Veterans Affairs, and while specific performance locations or points of contact are not specified, the delivery of the radiopharmaceutical is expected to align with the operational needs of VA medical facilities serving veterans. The absence of a set-aside designation suggests the contract is open to all eligible contractors without preference based on business size or category. Compliance with Good Manufacturing Practices and the ability to ensure consistent, reliable supply of Tc99m Bicisate with validated sterility and radiochemical purity are implicit requirements essential to patient safety and diagnostic accuracy.